J Breast Cancer.  2019 Sep;22(3):491-496. 10.4048/jbc.2019.22.e32.

Primary Histiocytic Sarcoma Presenting as a Breast Mass: A Case Report

  • 1Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea. charm@hanyang.ac.kr
  • 2Department of Surgery, College of Medicine, Hanyang University, Seoul, Korea.
  • 3Department of Radiology, College of Medicine, Hanyang University, Seoul, Korea.
  • 4Department of Nuclear Medicine, College of Medicine, Hanyang University, Seoul, Korea.


Histiocytic sarcoma is a rare hematologic malignancy, with very few cases of primary histiocytic sarcoma of the breast described in English scientific literature. Herein, we describe a case of primary histiocytic sarcoma of the breast in a 75-year-old woman, with no clinical history of malignant tumors, who presented with a palpable solitary breast mass. Microscopically, the resected breast mass showed large pleomorphic cells, some multinucleated giant cells, and admixed inflammatory components. The pleomorphic tumor cells further showed a diffuse, noncohesive growth pattern, an abundant eosinophilic cytoplasm, and strong and diffuse immunoreactivity for cluster of differentiation (CD) 68 and CD163. Furthermore, a whole-body positron-emission tomography/computed tomography using deoxy-2-[¹â¸F]fluoro-D-glucose performed after surgery showed no other masses or lesions. After surgical excision, the patient was followed up, and no evidence of tumor recurrence or metastasis was noted.


Breast; Histiocytes; Histiocytic sarcoma; True histiocytic lymphoma

MeSH Terms

Giant Cells
Hematologic Neoplasms
Histiocytic Sarcoma*
Neoplasm Metastasis


  • Figure 1 Breast ultrasonography shows a microlobulated hypoechoic mass in the right breast.

  • Figure 2 Histopathologic features of the histiocytic sarcoma. (A) The round solid mass is approximately 1.5 cm × 1.2 cm in size and is surrounded by breast tissue. (B) In the scanning view, the tumor is well-demarcated and shows high cellularity. (C) The tumor cells show a diffuse, noncohesive growth pattern and various admixed inflammatory components are also identified (hematoxylin-eosin stain, original magnification ×100). (D) Large atypical cells with an abundant eosinophilic cytoplasm as well as multinucleated giant cells are frequently observed. Mitosis is also easily observed. (hematoxylin-eosin stain, original magnification ×400).

  • Figure 3 Results of the immunohistochemistry (original magnification ×400). The tumor cells show strong and diffuse immunoreactivity for CD68 (A) and CD163 (B), and are negative for CD21 (C) and CD1a (D). CD = cluster of differentiation.


1. Kommalapati A, Tella SH, Durkin M, Go RS, Goyal G. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2018; 131:265–268.
2. Trevisan F, Xavier CA, Pinto CA, Cattete FG, Stock FS, Martins ML. Case report of cutaneous histiocytic sarcoma: diagnostic and therapeutic dilemmas. An Bras Dermatol. 2013; 88:807–810.
3. Petkova NY, Hristoskova RG, Guenova ML, Raynov JI. A rare case of primary histiocytic sarcoma of the stomach. Folia Med (Plovdiv). 2018; 60:318–322.
4. May JM, Waddle MR, Miller DH, Stross WC, Kaleem TA, May BC, et al. Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. Radiat Oncol. 2018; 13:167.
5. Yoshida C, Takeuchi M. Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry. Intern Med. 2008; 47:165–169.
6. Hornick JL, Jaffe ES, Fletcher CD. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004; 28:1133–1144.
7. Nangal JK, Kapoor A, Narayan S, Singhal MK, Beniwal S, Kumar HS. A case of CD68 negative histiocytic sarcoma of axilla masquerading as metastatic breast cancer. J Surg Case Rep. 2014; 2014:rju071.
8. Escandell I, Ramon MD, Sánchez S, Terradez L, Jorda E. Dermoscopic characteristics of a cutaneous histiocytic sarcoma in a young patient. J Am Acad Dermatol. 2017; 76:S5–7.
9. Skala SL, Lucas DR, Dewar R. Histiocytic sarcoma: review, discussion of transformation from B-cell lymphoma, and differential diagnosis. Arch Pathol Lab Med. 2018; 142:1322–1329.
10. Zhou J, Liu Y, Wang W, Xu FL. Histiocytic sarcoma of the neck: a case report. Mol Clin Oncol. 2018; 9:54–57.
11. Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, et al. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol. 2016; 97:9–16.
12. Go H, Jeon YK, Huh J, Choi SJ, Choi YD, Cha HJ, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014; 65:261–272.
13. Liu Q, Tomaszewicz K, Hutchinson L, Hornick JL, Woda B, Yu H. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. Virchows Arch. 2016; 469:233–241.
14. Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch. 2017; 471:467–489.
15. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002; 41:1–29.
Full Text Links
  • JBC
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr